Publications in collaboration with researchers from Charité (30)

2024

  1. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

  2. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five-Year International Observational Study

    ACR Open Rheumatology, Vol. 6, Núm. 2, pp. 103-110

2023

  1. Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

    Molecular Oncology, Vol. 17, Núm. 6, pp. 1060-1075

2022

  1. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results

    Rheumatology (United Kingdom), Vol. 61, Núm. 8, pp. 3299-3308

  2. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  3. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

  4. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Real-world outcomes using a spinal cord stimulation device capable of combination therapy for chronic pain: A european, multicenter experience

    Journal of Clinical Medicine, Vol. 10, Núm. 18

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

    American Heart Journal, Vol. 224, pp. 129-137

  2. Efficacy and Safety of Trastuzumab Emtansine plus Capecitabine vs Trastuzumab Emtansine Alone in Patients with Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

    JAMA Oncology, Vol. 6, Núm. 8, pp. 1203-1209

  3. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Frontiers in Neurology, Vol. 11

2019

  1. A Medication Adherence App for Children With Sickle Cell Disease: Qualitative Study

    JMIR mHealth and uHealth, Vol. 7, Núm. 6, pp. e8130

  2. A medication adherence app for children with sickle cell disease: Qualitative study

    JMIR mHealth and uHealth, Vol. 7, Núm. 6

  3. Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC)

    European Journal of Preventive Cardiology, Vol. 26, Núm. 7, pp. 709-727

  4. Exercise training to reduce cardiovascular risk in patients with metabolic syndrome and type 2 diabetes mellitus: How does it work?

    European Journal of Preventive Cardiology, Vol. 26, Núm. 7, pp. 701-708

2018

  1. A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial

    Intensive Care Medicine, Vol. 44, Núm. 11, pp. 1807-1815

2017

  1. Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis

    Neurosurgical Review, Vol. 40, Núm. 2, pp. 287-298